Lung cancer remains one of the deadliest malignancies worldwide, with non-small cell lung cancer (NSCLC) accounting for ~85% of cases. Despite advances in targeted therapies and immunotherapies, resistance and relapse remain major challenges. To uncover new therapeutic vulnerabilities, researchers are leveraging CRISPR-based functional genomic screens, enabling systematic identification of genes essential for cancer cell survival and drug response.
CRISPR-Cas9 genome editing allows high-throughput knockout of thousands of genes in cancer cells. By using pooled or arrayed sgRNA libraries, researchers can identify genes whose loss affects cell proliferation, survival, or drug sensitivity. Key steps include:
Library Design – sgRNAs target coding genes, non-coding regions, or specific pathways.
Cell Transduction – Lentiviral delivery of sgRNAs into lung cancer cell lines or patient-derived models.
Selection & Screening – Cells are subjected to drug treatment or growth conditions, and sgRNA abundance is quantified via next-generation sequencing (NGS).
Hit Identification – Bioinformatic analysis (e.g., MAGeCK, DESeq2) reveals essential genes and synthetic lethal interactions.
Genome-wide CRISPR screens have uncovered novel dependencies in lung cancer, such as:
KEAP1/NRF2 pathway – Mutations in KEAP1 confer oxidative stress resistance; targeting NRF2 may be therapeutic.
SWI/SNF complex genes (e.g., ARID1A, SMARCA4) – Loss of these genes creates vulnerabilities to EZH2 inhibitors.
CRISPR screens reveal genes that modulate drug response:
EGFR inhibitor resistance – Knockout of NF1 or YAP1 increases sensitivity to osimertinib.
Immunotherapy resistance – Loss of PTEN or STK11 reduces PD-1 blockade efficacy.
CRISPR screens identify context-specific vulnerabilities:
KRAS-mutant NSCLC – Combined inhibition of KRASG12C + SHP2 or KRAS + mTOR shows synergy.
TP53-deficient tumors – Dependency on WEE1 or ATR for cell cycle control.
While powerful, CRISPR screens face limitations:
Off-target effects – Improved sgRNA designs (e.g., CRISPRi/a) enhance specificity.
In vivo validation – Orthotopic mouse models and patient-derived organoids improve translatability.
Non-coding targets – CRISPR screens are expanding to regulatory elements and RNA-binding proteins.
CRISPR screens are revolutionizing lung cancer research by systematically uncovering novel drug targets, resistance mechanisms, and combinatorial therapies. Integrating these findings with clinical data will accelerate the development of precision oncology treatments, offering hope for improved patient outcomes.
